- Home
- TNYA vs ICCC Comparison
TNYA vs ICCC Comparison
Compare TNYA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- ICCC
- Stock Information
- Founded
- TNYA 2016
- ICCC 1982
- Country
- TNYA United States
- ICCC United States
- Employees
- TNYA N/A
- ICCC N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- ICCC Health Care
- Exchange
- TNYA Nasdaq
- ICCC Nasdaq
- Market Cap
- TNYA 73.8M
- ICCC 60.1M
- IPO Year
- TNYA 2021
- ICCC 1987
- Fundamental
- Price
- TNYA $0.69
- ICCC $6.39
- Analyst Decision
- TNYA Strong Buy
- ICCC
- Analyst Count
- TNYA 5
- ICCC 0
- Target Price
- TNYA $8.60
- ICCC N/A
- AVG Volume (30 Days)
- TNYA 2.3M
- ICCC 43.2K
- Earning Date
- TNYA 08-07-2025
- ICCC 08-14-2025
- Dividend Yield
- TNYA N/A
- ICCC N/A
- EPS Growth
- TNYA N/A
- ICCC N/A
- EPS
- TNYA N/A
- ICCC N/A
- Revenue
- TNYA N/A
- ICCC $27,302,766.00
- Revenue This Year
- TNYA N/A
- ICCC N/A
- Revenue Next Year
- TNYA N/A
- ICCC N/A
- P/E Ratio
- TNYA N/A
- ICCC N/A
- Revenue Growth
- TNYA N/A
- ICCC 28.29
- 52 Week Low
- TNYA $0.36
- ICCC $3.34
- 52 Week High
- TNYA $4.06
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- TNYA 62.18
- ICCC 54.37
- Support Level
- TNYA $0.58
- ICCC $6.21
- Resistance Level
- TNYA $0.70
- ICCC $6.86
- Average True Range (ATR)
- TNYA 0.05
- ICCC 0.64
- MACD
- TNYA 0.00
- ICCC -0.04
- Stochastic Oscillator
- TNYA 93.66
- ICCC 59.33
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.